恒瑞医药:子公司HRS-4139片获临床试验批准

智通财经
Yesterday
【恒瑞医药:子公司HRS-4139片获临床试验批准】恒瑞医药公告称,公司子公司福建盛迪医药有限公司收到国家药监局核准签发的HRS-4139片《药物临床试验批准通知书》,将于近期开展中重度斑块状银屑病的临床试验。HRS-4139片为公司自主研发1类新药,国内外暂无相同靶点药物获批上市,截至目前相关项目累计研发投入约2040万元。该药物尚需完成临床试验并通过审评审批后方可上市,研发及上市存在不确定性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10